Carotid Endarterectomy: Surgery for Blocked Carotid Arteries | My Medic Plus — Cost, Top Hospitals & Success Rates | MyMedicPlus

Carotid endarterectomy (CEA) is a vascular surgical operation performed to remove atheromatous plaque from the internal carotid artery, restoring unobstructed blood flow to the brain and reducing the risk of ischaemic stroke. The carotid arteries bifurcate in the neck at the level of the thyroid cartilage, and atherosclerotic plaque at this bifurcation — the most haemodynamically vulnerable location — causes stroke through two mechanisms: thromboembolism when plaque ruptures and fragments travel to the cerebral circulation, and haemodynamic ischaemia from flow-limiting high-grade stenosis.

CEA is performed through a longitudinal cervical incision exposing the carotid bifurcation under general or regional anaesthesia. The vessels are clamped, an arteriotomy is created, and the plaque's core is separated from the underlying media and adventitia using surgical dissection. A patch angioplasty — using bovine pericardium, Dacron, or a segment of saphenous vein — is sewn over the arteriotomy to widen the vessel lumen and prevent restenosis, a technique supported by Cochrane evidence as superior to primary closure.

CEA is one of the most extensively studied procedures in vascular surgery, validated by multiple large randomised controlled trials including NASCET, ECST, and ACAS. These landmark trials established CEA as the gold standard for stroke prevention in both symptomatic and carefully selected asymptomatic carotid stenosis, with an absolute stroke risk reduction of 6 to 17% over five years compared to optimal medical therapy alone. Modern perioperative stroke and death rates at experienced centres are 1 to 2% for symptomatic disease and below 3% for asymptomatic disease.

CEA is the definitive treatment for symptomatic internal carotid stenosis of 50% or greater diameter reduction by NASCET criteria, where the presenting event is an ipsilateral TIA, amaurosis fugax, or non-disabling stroke within the preceding six months. The benefit is greatest for stenosis of 70 to 99%, where NASCET demonstrated an absolute risk reduction of 17% in five-year ipsilateral stroke risk. Even for 50 to 69% symptomatic stenosis, CEA provides significant benefit (7.8% absolute risk reduction), especially in men and those with early surgery after the index event.

Asymptomatic carotid stenosis of 60 to 99% diameter reduction (ACAS criteria) is treated with CEA in patients under 75 years with low surgical risk and estimated life expectancy of at least five years, with an absolute five-year stroke risk reduction of 5.9% compared to aspirin alone (ACAS trial). Recurrent TIA despite optimal medical therapy, post-radiation carotid stenosis associated with prior head and neck cancer treatment, and carotid restenosis causing recurrent symptoms after prior CEA or carotid stenting are additional indications for surgical intervention.

An ideal candidate for CEA is a patient with recently symptomatic (within six months) internal carotid stenosis of 50 to 99%, confirmed on duplex ultrasound and validated by CTA or MRA, with a medical comorbidity profile that predicts a perioperative stroke and death risk below 6%. Guidelines emphasise urgent surgery within two weeks of TIA or minor stroke, as the ABCD2 score and imaging features predict very high early stroke risk that CEA rapidly eliminates. Patients with moderate (50 to 69%) stenosis benefit most when operated within two weeks of their index event.

Patients who are not suitable for CEA include those with complete internal carotid occlusion, tandem intracranial disease limiting cerebral perfusion benefit, or prohibitive operative risk from severe cardiac, pulmonary, or renal disease. Patients with recent major ischaemic stroke with significant disability should not undergo immediate CEA — a minimum of two to four weeks post-major stroke is generally recommended before surgery to avoid haemorrhagic transformation of the infarct. Anatomically hostile cases (high carotid bifurcation above C2, post-radiation fibrosis, previous ipsilateral CEA with restenosis) are better managed with carotid stenting (CAS).

Conventional CEA with patch angioplasty is the reference technique. The arteriotomy is extended longitudinally across the plaque, the atheromatous core is endarterectomised under loupe magnification, and the vessel is closed with a prosthetic or bovine pericardial patch. The Cochrane review of patch versus primary closure confirms patch angioplasty reduces restenosis from 10 to 15% to less than 5% at one year and significantly reduces perioperative stroke risk.

Eversion CEA involves transecting the internal carotid at its origin, everting the entire vessel to strip the plaque from within the cylinder, then re-anastomosing the vessel to the common carotid. This technique provides equivalent cerebrovascular protection with lower restenosis rates and avoids foreign body patch material. Intraoperative cerebral protection strategies include transcranial Doppler (TCD) monitoring for microemboli, EEG or SEP monitoring for ischaemia during clamping, and selective shunting (internal bypass from common to internal carotid) in patients whose cerebral monitoring indicates ischaemia during the trial clamping period. Regional anaesthesia (awake CEA) provides continuous neurological monitoring by testing contralateral hand grip and speech during surgery, allowing immediate shunt insertion if deficit occurs. The treating surgeon individualises the chosen technique based on patient anatomy, the extent and nature of the underlying condition, available equipment, and the balance of procedural benefit against risk — a decision made in consultation with the patient following a thorough informed consent discussion covering all available options.

For symptomatic 70 to 99% stenosis operated within two weeks, CEA provides a 90-day stroke risk reduction from approximately 18 to 20% with medical therapy to below 3%, one of the greatest absolute risk reductions in all of medicine. At five years, the absolute benefit is 17% stroke-free survival advantage. Carotid patency after patch CEA exceeds 95% at five years, with low rates of clinically significant restenosis. Successful CEA permanently eliminates the embolic source, removing the most dangerous period of high recurrent stroke risk.

Long-term outcomes are excellent: freedom from ipsilateral stroke exceeds 90% at 10 years post-CEA. The cranial nerve injuries that occur in 5 to 8% of patients are predominantly temporary, resolving within three to twelve months. Patients frequently report resolution of pre-operative symptoms including transient visual disturbance and hemispheric TIA symptoms, and haemodynamic improvement in cerebral perfusion can improve cognitive function in those with pre-operative hypoperfusion.

The major procedural risk of CEA is perioperative stroke, which occurs in 1.0 to 2.5% of cases at expert vascular centres performing more than 50 CEAs annually. This risk is the critical determinant of net benefit — patients must have a higher baseline stroke risk from the stenosis than the procedural risk to benefit from surgery. Myocardial infarction occurs in 0.5 to 1.5% of cases as a result of physiological stress and haemodynamic changes in a population with high background coronary artery disease prevalence.

Cranial nerve injuries affect 5 to 8% of patients, with the most common being hypoglossal nerve stretch (tongue deviation), marginal mandibular nerve injury (lower lip asymmetry), vagal injury (voice changes), and greater auricular nerve numbness at the ear lobe. Most are transient; permanent deficits occur in less than 1%. Wound haematoma requiring return to theatre occurs in 2 to 3% and must be recognised early as expanding haematoma can compromise the airway. Hyperperfusion syndrome — cerebral oedema and haemorrhage from sudden flow restoration — complicates 0.2 to 1% of high-grade stenosis repairs and requires immediate blood pressure reduction.

Postoperative monitoring in a high-dependency or vascular surgery step-down unit for 12 to 24 hours is standard, with particular attention to blood pressure (labile due to carotid sinus receptor manipulation), neurological status, and wound integrity. Aspirin 75 to 100 mg daily is continued perioperatively and indefinitely. Statin therapy targeting LDL below 1.8 mmol/L is mandatory for long-term plaque stabilisation. Blood pressure should be maintained between 100 and 160 mmHg systolic to prevent both hypoperfusion and hyperperfusion complications.

Hospital discharge on day one to two post-surgery is typical. Outpatient wound review at ten to fourteen days confirms healing and suture/clip removal. Duplex carotid ultrasound at one month and twelve months assesses patency and restenosis. Annual neurological and vascular review thereafter with repeat imaging if stenosis of 50% or greater is detected. Smoking cessation, antihypertensive therapy, antiplatelet therapy, and statin continuation are the pillars of post-CEA secondary stroke prevention.

Carotid endarterectomy in the United States costs USD 12,000 to USD 30,000 inclusive of hospitalisation, anaesthesia, operating room charges, and surgical fees, with emergency or urgent procedures incurring additional costs for rapid workup. Private CEA in the United Kingdom costs GBP 7,000 to GBP 14,000. The NHS provides CEA urgently for symptomatic patients as a priority procedure.

Medical tourism options for elective CEA offer significant savings. In India, CEA is available at USD 2,500 to USD 5,000 at tertiary vascular surgery centres with experienced surgeons and intraoperative monitoring capabilities. Turkey offers CEA for USD 4,000 to USD 8,000 at JCI-accredited hospitals. Patients must confirm the availability of vascular surgery ICU expertise and 24-hour postoperative neurological monitoring to ensure safe perioperative management comparable to Western standards.

Carotid artery stenting (CAS) with distal embolic protection devices is the endovascular alternative for patients who are high surgical risk for CEA. Multiple meta-analyses confirm that CAS carries higher periprocedural stroke risk than CEA in patients older than 70 years and in symptomatic disease, but similar outcomes in younger patients and asymptomatic disease. CAS is favoured for post-radiation stenosis, restenosis after prior CEA, high carotid bifurcation beyond surgical reach, and patients with prior ipsilateral neck surgery.

Optimal medical therapy (OMT) without revascularisation is appropriate for asymptomatic low-grade stenosis below 60%, complete occlusion (where intervention is futile), and patients with prohibitive operative or interventional risk. Contemporary OMT — high-intensity statin, antihypertensives, antiplatelet therapy, lifestyle modification — has substantially reduced the annual stroke risk of asymptomatic carotid stenosis, and the CREST-2 trial (2025 results awaited) will further clarify the role of revascularisation versus modern OMT in asymptomatic disease.